Urothelial carcinoma management in elderly or unfit patients

European Journal of Cancer, Supplement · Published 2016-03-01 · DOI 10.1016/j.ejcsup.2016.01.001

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ejcsup.2016.01.001

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2016

Related articles

• Inflammation and immunity in ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
• DNA damaging agents in ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
• The influence of secreted factors and extracellular vesicles in ovarian cancer metastasis · European Journal of Cancer, Supplement · 2020 · Same journal
• Cell proliferation inhibitors and apoptosis promoters · European Journal of Cancer, Supplement · 2020 · Same journal
• Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study · European Journal of Cancer, Supplement · 2021 · Same journal
• Biosimilars: Extrapolating the evidence. A roundtable discussion · European Journal of Cancer, Supplement · 2015 · Same journal
• Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? · European Journal of Cancer, Supplement · 2021 · Same journal
• Insight updating of the molecular hallmarks in ovarian carcinoma · European Journal of Cancer, Supplement · 2020 · Same journal
• Anti-angiogenic therapy for ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
• Rare ovarian tumours. Other treatments for ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal